Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis

Bibliography

• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92
   PubMed Web of Science ®Google Scholar
• American Cancer Statistics. 2011
   Google Scholar
• Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352(9141):1691-6
   Web of Science ®Google Scholar
• Porta C, Zimatore M, Imarisio I, Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution phase II study. Cancer 2004;100(10):2132-8
   Google Scholar
• DeVita VT, Hellman S, Rosenberg SA. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer principles and practice of oncology. Lippincott Williams & Wilkins; Philadelphia, PA; 2008
   Google Scholar
• Atkins MB, Regan M, McDermott D, Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18 II):6342s-6s
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338(18):1272-8
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A, Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110(11):2468-77
   PubMed Web of Science ®Google Scholar
• Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011;16(Suppl 2):45-50
   PubMedGoogle Scholar
• Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(Suppl 2):14-22
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Kidney Cancer. Version 1. 2013. NCCN.org
   Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC, EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58(3):398-406
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, editors. Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: phase 3 results from the INTORSECT trial. ESMO; Vienna: 2012
   Google Scholar
• Motzer R, Noscov D, Eisen T, Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;30(Suppl):abstract 4501
   Google Scholar
• Mills EJ, Bansback N, Ghement I, Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol 2011;3:193-202
   PubMedGoogle Scholar
• Porta C. How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shift. Eur Urol 2012;62(6):1020-1
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14(4):417-28
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical statistics for medical research. Chapman & Hall; Boca Raton: 1991
   Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14(4):429-37
   PubMed Web of Science ®Google Scholar
• Spiegelhalter D, Thomas AA, Best N, Lunn D. WinBUGS user manual: version 1.4. MRC Biostatistics Unit; Cambridge: 2003
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Negrier S, Jager E, Porta C, Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2010;27(3):899-906
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S, Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4068-75
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, O'Regan C, Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Casciano R, Malangone E, An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12(10):1491-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
   PubMed Web of Science ®Google Scholar
• Calvo E, Escudier B, Motzer RJ, Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48(3):333-9
   PubMed Web of Science ®Google Scholar
• Bracarda S, Hutson TE, Porta C, Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer 2012;24(9):1475-80
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Lebwohl D, Kay A, Berg W, Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009;15(5):386-94
   PubMed Web of Science ®Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101(23):1642-9
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011;29(Suppl):abstract 4503
   Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14(22):7272-83
   PubMed Web of Science ®Google Scholar
• Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011;11(2):113-26
   PubMedGoogle Scholar
• Casciano R, Malangone E, Sherman S, An indirect comparison of everloimus and sorafenib therapy in sunitinib-refractory mRCC patients. ASCO Annual Meeting; 4 – 8 June 2010; Chicago, IL; 2010
   Google Scholar
• McCann L, Amit O, Pandite L, Amado RG. An indirect comparison analysis of pazopanib versus opther agents in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15 Suppl):e15128
   Google Scholar
• Thompson Coon JS, Liu Z, Hoyle M, Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101(2):238-43
   PubMed Web of Science ®Google Scholar
• Knox JJ, Kay AC, Schiff E, First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15s Suppl):abstract TPS232
   Google Scholar
• NICE technology appraisal guidance 215. Pazopanib for the first-line treatment of advanced renal cell carcinoma; 2011.
   Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454-63
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40
   PubMed Web of Science ®Google Scholar